In This Article:
Shareholders will be ecstatic, with their stake up 27% over the past week following REGENXBIO Inc.'s (NASDAQ:RGNX) latest third-quarter results. The statutory results were mixed overall, with revenues of US$24m in line with analyst forecasts, but losses of US$1.17 per share, some 5.3% larger than the analysts were predicting. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
See our latest analysis for REGENXBIO
Taking into account the latest results, the most recent consensus for REGENXBIO from eleven analysts is for revenues of US$291.3m in 2025. If met, it would imply a major 245% increase on its revenue over the past 12 months. Losses are predicted to fall substantially, shrinking 93% to US$0.31. Before this latest report, the consensus had been expecting revenues of US$292.7m and US$0.55 per share in losses. While the revenue estimates were largely unchanged, sentiment seems to have improved, with the analysts upgrading their numbers and making a considerable decrease in losses per share in particular.
The average price target held steady at US$36.62, seeming to indicate that business is performing in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on REGENXBIO, with the most bullish analyst valuing it at US$52.00 and the most bearish at US$18.00 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's clear from the latest estimates that REGENXBIO's rate of growth is expected to accelerate meaningfully, with the forecast 170% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 3.2% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 21% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect REGENXBIO to grow faster than the wider industry.